REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN THE TREATMENT OF FIBROMYALGIA


The Study

The purpose of this project is to investigate the use of repetitive Transcranial Magnetic Stimulation (rTMS) as a potential treatment for the symptoms of fibromyalgia.

rTMS is a non-invasive method of brain stimulation which changes how excitable the cells of the brain are. Previous studies have shown differences in the activity in brain cells of people who experience fibromyalgia. rTMS may help to reduce fibromyalgia symptoms.

Who can participate in the study?

We are looking to recruit 40:

female participants with a diagnosis of fibromyalgia
aged between 18-65 years old

What’s involved

You will attend 20 sessions at Monash Alfred Psychiatry Research Centre (St Kilda Road, Melbourne) everyday (Monday-Friday) for four weeks.

During these sessions, you will undergo rTMS and be asked a number of questions about your pain and mood.

Prior to your enrolment in the trial, you will be randomly allocated to receive real or placebo rTMS. If you were allocated to the placebo group, you will have the opportunity to undergo the real rTMS treatment after your involvement in the study.

There are no costs associated with participating in this research project, nor will you be paid.

Closing Date

Recruitment closes July 2017.

Ethics and Funding

The ethical aspects of this research project have been approved by the HREC of Alfred Hospital, Monash University and Monash Health (Ethics Committee Project Number: 249/13).

Contact Information

If you are interested in hearing more about this research, please contact:
Dr Bernadette Fitzgibbon
Telephone: 9076 9860
Email: Bernadette.Fitzgibbon@monash.edu



Musculoskeletal Australia (or MSK) is the consumer organisation working with, and advocating on behalf of, people with arthritis, osteoporosis, back pain, gout and over 150 other musculoskeletal conditions.

Useful Links

Health DirectHealth DirectHealth Direct

Copyright by Musculoskeletal Australia 2018. All rights reserved.

ABN: 26 811 336 442ACN: 607 996 921